Immunogenicity and Safety of GSK Biologicals' Influenza Vaccine Versus a Licensed Comparator in Children

PHASE3CompletedINTERVENTIONAL
Enrollment

3,317

Participants

Timeline

Start Date

October 1, 2008

Primary Completion Date

March 5, 2009

Study Completion Date

June 1, 2009

Conditions
Influenza
Interventions
BIOLOGICAL

Fluarix

One (Day 0) or two (Day 0 and Day 28) doses by intramuscular injection. Two different doses are tested.

BIOLOGICAL

Fluzone

One (Day 0) or two (Day 0 and Day 28) doses by intramuscular injection.

Trial Locations (69)

104

GSK Investigational Site, Taipei

6720

GSK Investigational Site, México

10400

GSK Investigational Site, Bangkok

13045

GSK Investigational Site, Cortland

15090

GSK Investigational Site, Wexford

15236

GSK Investigational Site, Pittsburgh

15401

GSK Investigational Site, Uniontown

15650

GSK Investigational Site, Latrobe

16125

GSK Investigational Site, Greenville

16505

GSK Investigational Site, Erie

22015

GSK Investigational Site, Burke

27518

GSK Investigational Site, Cary

27609

GSK Investigational Site, Raleigh

28607

GSK Investigational Site, Boone

29406

GSK Investigational Site, Charleston

35205

GSK Investigational Site, Birmingham

35244

GSK Investigational Site, Birmingham

36305

GSK Investigational Site, Dothan

37043

GSK Investigational Site, Clarksville

37660

GSK Investigational Site, Kingsport

38305

GSK Investigational Site, Jackson

40004

GSK Investigational Site, Bardstown

40207

GSK Investigational Site, Louisville

44121

GSK Investigational Site, Cleveland

44515

GSK Investigational Site, Austintown

45245

GSK Investigational Site, Cincinnati

45406

GSK Investigational Site, Dayton

47150

GSK Investigational Site, New Albany

49127

GSK Investigational Site, Stevensville

55108

GSK Investigational Site, Saint Paul

58103

GSK Investigational Site, Fargo

60115

GSK Investigational Site, DeKalb

63141

GSK Investigational Site, St Louis

67005

GSK Investigational Site, Arkansas City

67114

GSK Investigational Site, Newton

67207

GSK Investigational Site, Wichita

68134

GSK Investigational Site, Omaha

70006

GSK Investigational Site, Metairie

71111

GSK Investigational Site, Bossier City

72019

GSK Investigational Site, Benton

72034

GSK Investigational Site, Conway

72205

GSK Investigational Site, Little Rock

72401

GSK Investigational Site, Jonesboro

72703

GSK Investigational Site, Fayetteville

76135

GSK Investigational Site, Fort Worth

76904

GSK Investigational Site, San Angelo

77055

GSK Investigational Site, Houston

78705

GSK Investigational Site, Austin

80501

GSK Investigational Site, Longmont

83686

GSK Investigational Site, Nampa

84010

GSK Investigational Site, Bountiful

84041

GSK Investigational Site, Layton

84067

GSK Investigational Site, Roy

84095

GSK Investigational Site, South Jordan

84107

GSK Investigational Site, Murray

84604

GSK Investigational Site, Provo

89015

GSK Investigational Site, Henderson

90723

GSK Investigational Site, Paramount

90806

GSK Investigational Site, Long Beach

91790

GSK Investigational Site, West Covina

92647

GSK Investigational Site, Huntington Beach

94102

GSK Investigational Site, San Francisco

95816

GSK Investigational Site, Sacramento

97030

GSK Investigational Site, Gresham

06360

GSK Investigational Site, Norwich

Unknown

GSK Investigational Site, Pokfulam

GSK Investigational Site, Shatin

GSK Investigational Site, Taipei

04530

GSK Investigational Site, Mexico City

Sponsors

Lead Sponsor

All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY

NCT00764790 - Immunogenicity and Safety of GSK Biologicals' Influenza Vaccine Versus a Licensed Comparator in Children | Biotech Hunter | Biotech Hunter